信迪利单抗注射液治疗晚期恶性肿瘤的疗效和安全性分析

Efficacy and safety analysis of sindelizumab injection in the treatment of advanced malignant tumor

目的探讨信迪利单抗注射液联合治疗晚期恶性肿瘤的疗效和安全性。方法选取68例接受信迪利单抗注射液联合化疗或靶向药物治疗的晚期恶性肿瘤患者作为观察组,另选取30例接受化疗或靶向治疗的晚期恶性肿瘤患者作为对照组,比较两组患者临床疗效以及不良反应发生情况。结果治疗前后观察组患者靶病灶最大径缩小值为(33.45±11.16)mm,大于对照组的(27.54±9.15)mm,差异有统计学意义(P﹤0.05)。观察组患者客观缓解率(ORR)和疾病控制率(DCR)均高于对照组,差异均有统计学意义(P﹤0.05)。观察组患者发生G_(1)~G_(2)级不良反应41例(60.3%),G_(3)级不良反应8例(11.8%)。观察组患者对不良反应均能耐受,不影响后续治疗。结论信迪利单抗联合化疗或靶向药物治疗晚期恶性肿瘤疗效较好,患者不良反应可耐受。

Objective To investigate the efficacy and safety of sindelizumab injection in the treatment of advanced malignant tumor.Method A total of 68 patients with advanced malignant tumors who received sindelizumab injection combined with chemotherapy or targeted drug therapy were selected as the observation group.Another 30 patients with advanced malignant tumors who received chemotherapy or targeted therapy were selected as the control group.The clinical efficacy and adverse events of the two groups were compared.Result The maximum diameter of the target lesion decreased to(33.45±11.16)mm in the observation group before and after the treatment,which was bigger than the control group with(27.54±9.15)mm,the difference was statistically significant(P<0.05).The objective response rate(ORR)and disease control rate(DCR)in the observation group were higher than those in the control group,the differences were statistically significant(P<0.05).41 patients(60.3%)had grade G_(1)-G_(2) adverse reactions and 8 patients(11.8%)had grade G_(3) adverse reactions in the observation group.The patients in the observation group could tolerate the adverse events,which did not affect the subsequent treatment.Conclusion The combination therapy including sindelizumab with chemotherapy or targeted drug therapy has a good curative effect in the treatment of advanced malignant tumors with endurable adverse events.